Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · IEX Real-Time Price · USD
3.130
+0.010 (0.32%)
At close: Jul 2, 2024, 4:00 PM
3.140
+0.010 (0.32%)
After-hours: Jul 2, 2024, 6:03 PM EDT
Arbutus Biopharma Revenue
Arbutus Biopharma had revenue of $12.99M in the twelve months ending March 31, 2024, down -60.80% year-over-year. Revenue in the quarter ending March 31, 2024 was $1.53M, a -77.09% decrease year-over-year. In the year 2023, Arbutus Biopharma had annual revenue of $18.14M, a decrease of -53.51%.
Revenue (ttm)
$12.99M
Revenue Growth
-60.80%
P/S Ratio
45.49
Revenue / Employee
$177,890
Employees
73
Market Cap
590.68M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
Dec 31, 2020 | 6.91M | 903.00K | 15.02% |
Dec 31, 2019 | 6.01M | 66.00K | 1.11% |
Dec 31, 2018 | 5.95M | -4.76M | -44.44% |
Dec 31, 2017 | 10.70M | 9.21M | 617.64% |
Dec 31, 2016 | 1.49M | -21.79M | -93.59% |
Dec 31, 2015 | 23.28M | 8.32M | 55.66% |
Dec 31, 2014 | 14.95M | -512.00K | -3.31% |
Dec 31, 2013 | 15.47M | 1.36M | 9.64% |
Dec 31, 2012 | 14.11M | -2.71M | -16.10% |
Dec 31, 2011 | 16.81M | -4.54M | -21.27% |
Dec 31, 2010 | 21.35M | 6.93M | 48.00% |
Dec 31, 2009 | 14.43M | 2.70M | 22.99% |
Dec 31, 2008 | 11.73M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.00B |
Varex Imaging | 855.80M |
Fulgent Genetics | 287.53M |
Castle Biosciences | 250.73M |
Arcturus Therapeutics Holdings | 124.53M |
Zymeworks | 50.46M |
Lexicon Pharmaceuticals | 2.31M |
ABUS News
- 26 days ago - Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels - GlobeNewsWire
- 27 days ago - Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure - GlobeNewsWire
- 4 weeks ago - Arbutus Distributors Ltd. News Release - GlobeNewsWire
- 4 weeks ago - Arbutus to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Arbutus to Present Imdusiran Data at EASL Congress 2024 - GlobeNewsWire
- 6 weeks ago - Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value - Business Wire
- 2 months ago - Arbutus to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire